Early use of sodium nitroprusside in respiratory distress syndrome.

Beverley, D W; Hughes, Carolyn S.; Davies, D P; Harran, M. J.; Ducker, D A

doi:10.1136/adc.54.5.403

Cited by 16 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNP is recommended, inter alia, for use in children for providing controlled hypotension during surgery [2], for treating hypertensive crisis [5--7]~ congestive heart failure [4] and respiratory distress syndrome [1,3]. Turmen We have demonstrated elsewhere [8] that in treating adult patients with SNP, the only safe way of ensuring that cyanide does not accumulate in the body is to infuse thiosulphate together with the SNP.…”

Section: Discussionmentioning

confidence: 99%

Detoxification of cyanide in a new-born child

Schulz

Roth

1982

Klin Wochenschr

View full text Add to dashboard Cite

A well-developed male baby was given infusions of 2-5 microgram/kg/min of sodium nitroprusside (SNP) in the first few days after birth on account of high arterial blood pressure. After 30 h of treatment, cyanide accumulation was found to have reached a life-threatening level. IV administration of 100 mg/kg of sodium thiosulphate promptly lowered the cyanide level. The mixed infusion of SNP together with thiosulphate, used in the subsequent course, was no longer toxic.

show abstract

Section: Discussionmentioning

confidence: 99%

Detoxification of cyanide in a new-born child

Schulz

Roth

1982

Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…however, increased shunt fraction and decreased arterial oxygenation make sildenafil unsuitable for the treatment of patients with ARDS (Cornet et al, 2010). Information on the use of nitrovasodilators in ARDS is scarce, and there is no convincing evidence to justify their use (Beverley et al, 1979;Benitz et al, 1996). NO-GC stimulators/activators have not yet been established for pulmonary distress.…”

Section: Acute Respiratory Distress Syndrome (Ards)mentioning

confidence: 99%

“…However, increased shunt fraction and decreased arterial oxygenation make sildenafil unsuitable for the treatment of patients with acute respiratory distress syndrome (Cornet, Hofstra, Swart, Girbes, & Juffermans, 2010). Information on the use of nitrovasodilators in acute respiratory distress syndrome is scarce, and there is no convincing evidence to justify their use (Benitz, Rhine, Van Meurs, & Stevenson, 1996; Beverley, Hughes, Davies, Harran, & Ducker, 1979). NO‐GC stimulators/activators have not yet been established for pulmonary distress.…”

Section: Adult Lung Diseasesmentioning

confidence: 99%

NO‐sensitive guanylyl cyclase in the lung

Friebe

Englert

2021

British J Pharmacology

View full text Add to dashboard Cite

In the late 1960s, several labatories identified guanylyl cyclase (GC) as the cGMP‐producing enzyme. Subsequently, two different types of GC were described that differed in their cellular localization. Primarily found in the cytosol, nitric oxide (NO)‐sensitive guanylyl cyclase (NO‐GC) acts as receptor for the signalling molecule NO, in contrast the membrane‐bound isoenzyme is activated by natriuretic peptides. The lung compared with other tissues exhibits the highest expression of NO‐GC. The enzyme has been purified from lung for biochemical analysis. Although expressed in smooth muscle cells (SMCs) and in pericytes, the function of NO‐GC in lung, especially in pericytes, is still not fully elucidated. However, pharmacological compounds that target NO‐GC are available and have been implemented for the therapy of pulmonary arterial hypertension. In addition, NO‐GC has been suggested as drug target for the therapy of asthma, acute respiratory distress syndrome and pulmonary fibrosis. LINKED ARTICLES This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc

show abstract

“…Experimental data regard ing nitroprusside's effect in neonates are unavailable. Its clinical usefulness in neonatal pulmonary hypertensive states is currently anecdotal [1,7] and neither clearly efficacious [85] nor safe [94].…”

Section: Organic Nitratesmentioning

confidence: 99%